Merck (MRK) ended the recent trading session at $110.18, demonstrating a -1.7% swing from the preceding day's closing price. This change lagged the S&P 500's 0.17% loss on the day. Meanwhile, the Dow ...

Shares of Merck Merck & Co. Inc. and Intel Intel Corp. have contributed to the blue-chip gauge's intraday decline, as the Dow Dow Jones Industrial Average was most recently trading 290 points, or 0.7% ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the completion of the acquisition of ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Merck & Co. has picked up options on two Evaxion vaccine candidates, paying $3.2 million and dangling more than $1 billion in ...

Merck said on Wednesday a combination of its experimental drug and blockbuster therapy Keytruda failed a late-stage trial ...

Shares of Merck (NYSE:MRK) traded marginally higher on Friday after falling from a high of $119.38 from the past seven ...

Merck's Phase 3 KEYFORM-007 study on the combination of favezelimab and pembrolizumab in MSS mCRC patients did not improve ...

An attempt by Merck & Co. to unlock the microsatellite stable (MSS) metastatic colorectal cancer market has ended in failure.

Merck follows in the footsteps of Bristol Myers Squibb, which in December 2023 also failed to secure a late-stage victory for ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, will hold its third-quarter 2024 sales and earnings conference call with institutional investors and analysts at 9:00 a.m ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, will hold its third-quarter 2024 sales and earnings conference call with institutional investors and analysts at 9:00 a.m. ET ...